Clinical TrialsSearch results
Number of results: 508
Recruiting
- Suppression of awake bruxism by using an oral appliance
- awake bruxism
- Kodama Naoki
- 2024-03-18
Recruiting
- SUPPORT-pVAD
- Cardiogenic shock
- Kazufumi Nakamura
- 2023-05-20
Other
- Subepithelial injection of botulinum toxin A for non-neurogecic overactive bladder
- Non-neurogenic overactive bladder
- National Center for Geriatrics & Gerontology
- 2008-10-14
Recruiting
- Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents with Osteogenesis Imperfecta
- Osteogenesis Imperfecta
- Asato Keita
- 2024-02-28
Completed
- Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection
- Complicated Intra-abdominal Infection
- Kawai Norisuke
- 2021-07-21
Other
- Study on Therapeutic Effects of Antiplatelet Drugs in Prevention of Occurrence and Inhibition of Progression of Diabetic Atherosclerosis
- Diabetes
- DAPC Study Steering Committee
- 2005-10-01
No Longer Recruiting
- Study of TAE added on chemotherapy in patients with metastatic neuroendocrine tumors
- Gastroenteropancreatic neuroendocrine neoplasms
- Kato Hironari
- 2021-06-21
Other
- Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With HR+/HER2- Metastatic Breast Cancer Who Have Received Endocrine Therapy
- HR+/HER2- inoperable, locally advanced, or metastatic breast cancer who have received prior ET
- Akiyama Masanao
- 2023-06-29
Recruiting
- Study of KTE-X19 in Adult Japanese Subjects with Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
- Relapsed/Refractory (r/r) Mantle Cell Lymphoma or r/r B-precursor Acute Lymphoblastic Leukemia
- Asou Hiroya
- 2024-01-30
Other
- Study of imatinib monotherapy and combination of imatinib with IFN or cytarabine ocfosfate for chronic-phase CML (JALSG CML202 Study)
- Previously untreated chronic-phase chronic myelogenous leukemia
- Japan Adult Leukemia Study Group
- 2005-09-10